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The multiple mechanisms of action for ﬂavocoxid relating to arachidonic acid (AA) formation and metabolism were studied in
vitro. Flavocoxidtitrated into ratperitoneal macrophagecultures inhibited cellularphospholipaseA2(PLA2)( I C 50 =60μg/mL).In
in vitro enzyme assays,ﬂavocoxidshowed little anti-cyclooxygenase(CO) activity onCOX-1/-2 enzymes, but inhibited the COX-1
(IC50 = 12.3) and COX-2 (IC50 = 11.3μg/mL) peroxidase (PO) moieties as well as 5-lipoxygenase (5-LOX) (IC50 = 110μg/mL).
No detectable 5-LOX inhibition was found for multiple traditional and COX-2 selective NSAIDs. Flavocoxid also exhibited strong
and varied antioxidant capacities in vitro and decreased nitrite levels (IC50 = 38μg/mL) in rat peritoneal macrophages. Finally,
in contrast to celecoxib and ibuprofen, which upregulated the cox-2 gene, ﬂavocoxid strongly decreased expression. This work
suggests that clinically favourable eﬀects of ﬂavocoxid for management of osteoarthritis (OA) are achieved by simultaneous
modiﬁcation of multiple molecular pathways relating to AA metabolism, oxidative induction of inﬂammation,and neutralization
of reactive oxygen species (ROS).
1.Introduction
Osteoarthritis is a multifactorial disease, often caused by
injury or repetitive trauma, and involves metabolic as well
as inﬂammatory components. Constant “wear-and-tear” on
joints leads to the release of phospholipids from damaged
cells which are then converted by PLA2 into AA [1]. Dietary
habits, particularly excess consumption of AA in the form of
omega-6 fatty acids, have been shown to impact the extent
and progression of OA in humans [2]. Through the action of
the COX and 5-LOX enzymes, AA from tissue destruction
and diet is converted into inﬂammatory metabolites such
as thromboxane (TX), prostaglandins (PGs), prostacyclins
(PCs), and leukotrienes (LTs) [3, 4].
Flavocoxid, marketed as Limbrel, is a USFDA-regulated
prescription medical food (CFR Volume 21 USC [Code]
section 360ee (b)(3)) for the clinical dietary management of
the metabolic processes of OA. The molecules in ﬂavocoxid
were isolated by high-throughput screening of thousands
of natural extracts having anti-PO, COX-1 and COX-2
activity as well as 5-LOX enzyme inhibition [5]. The product
is composed of a proprietary mixture of the ﬂavonoid
moleculesbaicalin,extractedfromScutellaria baicalensis,a n d
catechin, from Acacia catechu, concentrated to greater than
90% purity (Figure 1)[ 6].
Recent clinical eﬃcacy trials utilizing Garcinia kola
[7], pine bark extract-derived bioﬂavonoids [8, 9], and
ﬂavocoxid itself [10–12] demonstrate a renewed interest
in the use of natural molecules for the management of
OA. The exact mechanism of action of ﬂavonoid-based
therapeutics is unknown. Using a variety of in vitro enzyme,
cell, gene expression, and antioxidant assays, we examined
the anti-inﬂammatory mechanism of action of ﬂavocoxid.2 Mediators of Inﬂammation
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Figure 1: Flavocoxid (a) baicalin and (b) catechin.
Flavocoxid’s inhibitory activity on PLA2 as well as its
exact interaction with the COX and 5-LOX enzymes was
clariﬁed. In addition, the broad antioxidant capacity of
ﬂavocoxid and its eﬀect on nitrite production in a cell model
was determined and related to its damping of cox-2 gene
expression compared to other anti-inﬂammatory agents.
These pleiotropic, anti-inﬂammatory eﬀects of ﬂavocoxid
are discussed, correlating this in vitro characterization to in
vivo safety and eﬃcacy results in humans for the clinical
management of OA.
2.Materialsand Methods
2.1. Materials. The following NSAIDs were purchased from
Sigma-Aldrich(St.Louis,Mo,USA):meloxicam, sodiumsalt
(#3935); naproxen, sodium salt (#5160); diclofenac, sodium
salt (#D6899); ibuprofen, sodium salt (#I1892) and NS-398
(#N194). Rofecoxib was purchased from Merck & Co. Inc.
(Whitehouse Station, NJ, USA), and valdecoxib and celecox-
ib from Pﬁzer (New York, NY, USA). Flavocoxid, as well as
90% pure baicalin and 90% pure catechin, were provided
by Primus Pharmaceuticals, Inc. (Scottsdale, Ariz, USA).
Each compound was dissolved in 100% dimethyl sulfox-
ide (DMSO; Sigma-Aldrich). Flavocoxid is a mixture of
compounds with diﬀerent molecular weights. Therefore, all
concentrations are given in μg/ml for the compounds tested
rather than micromolar concentrations.
2.2. Methods
2.2.1. Animals and Isolation of Peritoneal Macrophages for
Nitrite Determination and Phospholipase A2 Assay. All pro-
cedures complied with the standards for care and use of
animal subjects as stated in the Guide for the Care and
Use of Laboratory Animals (Institute of Laboratory Animal
Resources, National Academy of Sciences, Bethesda, Md,
USA). Peritoneal macrophages were obtained from male
Sprague–Dawley rats (250–275g) by washing the abdominal
cavity with RPMI 1640. The cells were centrifuged twice
and resuspended in the same medium at a concentration of
3 × 106/mL Macrophages were puriﬁed after 2h adhesion to
plastic Petri dishes (Nunc, Roskilde, Denmark) at 37◦C. The
homogeneity and the viability of macrophages were greater
than 98% as determined by diﬀerential staining and trypan
blue exclusion. Macrophages were stimulated for 6 h with
1μg/mL of lipopolysaccharide (LPS). Lipopolysaccharide-
stimulated macrophages were coincubatedwith ﬂavocoxidat
10, 20, 50, 100, 200, and 500g/mL or RPMI medium alone.
Cell Viability. Cell viability of peritoneal macrophages,
following exposure to ﬂavocoxid (from 10, 20, 50, 100,
200 and 500μg/mL) and/or with 1μg/mL LPS at 37◦C,
was determined after 24h of incubation by the MTT
[3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bro-
mide] assay, as described by Mosmann [13].
Phospholipase A2 Assay. Phospholipase A2 was assayed in
cytosolic extract by using the cPLA2 Assay kit (Cayman, Ann
Arbor, Mich, USA) following the manufacturer’s protocol.
Brieﬂy cells were homogenized in lysis buﬀer (50mM Hepes
pH 7.4, 1mM EDTA), sonicated and then centrifuged at
10.000 × gf o r1 5m i na t4 ◦C. The supernatant was removed
for the assay and stored on ice. Absorbance was read at
OD414nm, and results were compared to the positive control
(bee venom PLA2).
2.2.2. Puriﬁed Enzyme Assays to Test Flavocoxid’s Eﬀect on
COX-1 and COX-2 Cyclooxygenase and Peroxidase
Activities and 5-LOX Inhibition
COX-1 and COX-2 Cyclooxygenase Inhibition Assay. Flavo-
coxid was dissolved in 100% DMSO at a stock concentration
of 10mg/mL. Flavocoxid was tested in triplicate at 0, 0.1,
1, 10 and 50μg/mL. DMSO alone alters oxygenase activity.
Therefore, the highest concentration of ﬂavocoxidthat could
be tested using the oxygraph assay (Cayman Chemical
Company, Inc.) to determine CO-speciﬁc inhbition without
interference was 50μg/mL. Indomethacin (MW = 357.8)and
NS-398 (MW = 314.4) were run as positive controls for
inhibition of COX-1 and COX-2, respectively. Indomethacin
was tested in triplicate at 0, 3.6, 18, 36, 180, and 360 ng/mL.
NS-398 was tested in triplicate at 0, 3.1, 15.7, 31.4, 157
and 314ng/mL. These inhibitors were pre-incubated with
the enzyme in reaction buﬀer for one minute prior to the
addition of AA. Assays were performed using 100 units of
ovine COX-1or ovine COX-2(oneunitof enzymeconsumesMediators of Inﬂammation 3
one nanomole of oxygen per minute at 37◦Ci n0 . 1MT r i s -
HCl buﬀer, pH 8.0, containing 20μM AA, 5 mM EDTA, 2
mM phenol,and 1μM hematin). Assays were initiated by the
addition of 20μM AA, and oxygen consumption measured
using a Gilson Model 5/6H oxygraph equipped with a Clark
oxygen electrode [14].
COX-1 and COX-2 Peroxidase Inhibition Assays. Ac l e a v -
able, peroxide chromophore (N,N,N N -Tetramethyl-p-
phenylenediamine dihydrochloride (TMPD)) (Sigma) was
included in the assay to measure the inhibitor eﬀect on PO
activity of COX-1 and COX-2 in the presence of AA as
ac o f a c t o r[ 15]. Each inhibitor was tested for PO-speciﬁc
inhibition in triplicate (Cambridge Biomedical Research
Group, Inc.), at room temperature (25◦C) over a range of
concentrations from 0 to 500μg/mL using ovine COX-1
and COX-2 enzymes (provided by Cayman Chemical, Ann
Arbor, Mich, USA), hematin (Sigma), TMPD (Sigma), and
AA (Sigma). Absorbance of the cleaved TMPD substrate
was read at OD570nm. The mean results for each inhibitor
concentration versus percentage inhibition was plotted, and
the IC50 determined by taking the half-maximal point along
the isotherm and intersecting the concentration on the x-
axis.
5-LOX Inhibition Assay. A Lipoxygenase Inhibitor Assay
Kit (Cayman Chemical) was used in which potato 5-LOX
(Cayman Chemical) was substituted for the soy 15-LOX
usually present in the kit. The buﬀer was also changed from
phosphate buﬀer, pH 6.8 to a Tris-HCl, pH 7.4 buﬀer and
was used to measure 5-LOX inhibition for each inhibitor.
This assay detects the formation of unstable hyperoxides,
HPETEs, which are then converted to LTs through an oxygen
sensing chromagen system consisting of FeSO4·7H2Oa n d
NH4SCN that changes to bright yellow [16]. The assay
was performed in triplicate using potato 5-LOX (15.3
units), linoleic acid (LA) as a cofactor, and TMPD as a
substrate with a variety of inhibitors titrated from 0 to
500μg/mL and ﬂavocoxid from 0 to 1000μg/mL at room
temperature. Absorbance of the cleaved TMPD substrate
was read at OD500nm. The mean results for each inhibitor
concentration versus percentage inhibition was plotted and
the IC50 determined by taking the half-maximal point along
the isotherm and intersecting the concentration on the x-
axis.
2.2.3. In Vitro Antioxidant Capacity Assays of Flavocoxid
Nitrite Production. Nitrite levels, a breakdown product of
nitric oxide (NO), were measured in a standard Griess
reaction. Brieﬂy, 100μL of LPS-stimulated macrophage
supernatants with and without ﬂavocoxid were incubated
with an equal volume of Griess reagent (1% sulphanil-
amide and 0.1% naphthyl-ethylenediamine dihydrochloride
in 2.5% phosphoric acid). After 10min of incubation at
room temperature, the absorbance of the chromophore
was measured at OD540nm using a microtitre plate reader.
Nitrite concentrations were calculated by comparison with a
standard calibrationcurve with sodium nitrite (NaNO2:1.26
to 100mM), with control baseline supernatant as the blank.
Antioxidant Assays. The in vitro antioxidant activity of ﬂavo-
coxid was evaluated using Oxygen Radical Absorbance Ca-
pacity (ORAC) procedures (Brunswick Laboratories, Nor-
ton, Mass, USA). Values are expressed as μmol of Trolox
equivalents(TE)pergofdry weightand comparedtoknown
values for vitamins C and E. The ORAC analysis provides a
measure of the scavenging capacity of antioxidants against
the peroxyl radical, which is one of the most common
ROS found in the body. ORAChydro reﬂects water-soluble
antioxidant capacity, and the ORAClipo is the lipid soluble
antioxidant capacity. Trolox, a water-soluble Vitamin E
analog, is used as the calibration standard, and the ORAC
result is expressed as μmol TE/g dry weight.
The ferric reducing/antioxidant power (FRAP) assay was
performed as previously described [17]. A validated assay
for hydroxyl radical absorbance capacity (HORAC) was
also performed according to described methods [18]. The
peroxynitrite radical averting capacity assay (NORAC) and
superoxide radical averting capacity (SORAC) assays were
performed as described previously [19].
Other antioxidant capacity assays used in the anal-
ysis of ﬂavocoxid’s antioxidant capacity include TEAC
(troloxequivalentantioxidantcapacity),amethoddeveloped
by Rice-Evans’ group and broadly applied in analyzing
food samples [20] and DPPH [2,2-di(4-tert-octylphenyl)-
1-picrylhydroxyl], an easy and accurate method frequently
used to measure the antioxidant capacity of fruit and
vegetable juices and extracts [21].
2.2.4. Eﬀects of Flavocoxid, Celecoxib, Ibuprofen, and Ace-
tominophen on cox-1 and cox-2 Gene Expression. Human
peripheral blood mononuclear cells (PBMCs) were isolated
from apheresis products (COBE Laboratories, Inc.) using a
Histopaque density gradient [22]a n dc o c u l t u r e da t∼4.5 ×
106 cells in 3mL growth medium per well in 6-well plates
with LPS at 10ng/mL at 37◦C in a humid environment with
5% CO2. The samples were collected 18hr posttreatment.
Total RNAs were prepared using the Qiagen RNeasy Kit
and cDNAs synthesized using the ABI cDNA Archive kit,
following the protocols of the suppliers. QPCR assays were
run in duplicate in an ABI 7700 Sequence Detector using
ABI TaqMan Gene Expression primer and probe sets for
COX-1 and COX-2. Flavocoxid was compared to celecoxib,
ibuprofen, and acetaminophen all at 3μg/mL for theireﬀects
on cox-1 and cox-2 expression. Cyclophilin A was used as
thereferencetranscript fortherelativequantiﬁcationofRNA
levels to normalize gene expression.
2.3. Statistical Analysis. All data are expressed as the mean ±
SD. Data were assessed by analysis of variance for multiple
comparisons of results. The Duncan multiple range test was
usedtocomparegroupmeans. Inallcases,aprobabilityerror
of less than .05 was selected as the criterion for statistical
signiﬁcance.4 Mediators of Inﬂammation
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Figure 2: Cellular phospholipase A2 activity in rat peritoneal
macrophages exposed to ﬂavocoxid (F) at 10, 20, 50, 100, 200, and
500μg/mL in the presence of lipopolysaccharide (LPS).
3.Results
PLA2 Inhibitory Activity. Other well researched ﬂavonoids,
such as green tea catechins and quercitin have been shown
to inhibit PLA2 thus modulating the generation of AA from
membrane phospholipids [23, 24]. Little is known, however,
regarding the direct inhibitory eﬀects of either baicalin or
catechinonPLA2 activity. Therefore, ﬂavocoxid was tested in
a macrophage cell assay for its ability to inhibit PLA2 activity.
Flavocoxid had a minor, nonstatistical eﬀect on
macrophage cell viability at 200 and 500μg/mL (data not
shown). Phospholipase A2 inhibition levels were corrected
for cell viability. When ﬂavocoxid was titrated into LPS-
stimulated rat peritoneal macrophage cultures, it exhibited
a dose response inhibition of PLA2 (IC50 = 60μg/mL) at
concentrations of 50, 100, 200, and 500μg/mL signiﬁcantly
better than LPS alone (P<. 05) (Figure 2). This result
suggests that ﬂavocoxid has the ability to modulate the
generation of AA from membrane phospholipids produced
by the destruction of tissue which occurs in OA.
COX-1 and COX-2 Cyclooxygenase Inhibitory Activity. The
COX proteins contain two diﬀerent enzymatic moieties for
metabolism of AA, cyclooxygenase (CO) and peroxidase
(PO). The CO activity converts AA to PGG2 and the PO
activity metabolizes PGG2 toPGH2 [25].Subsequentplatelet
and cellular synthases as well as isomerases then convert
PGH2 to TX as well as PGs and PCs. Medications used to
treat OA, such as traditional NSAIDs and selective COX-2
inhibitors, block the production of PGG2, but do not aﬀect
the PO site. Flavocoxid was tested for its speciﬁc CO and
PO inhibition using puriﬁed enzymes in vitro to deﬁne its
speciﬁc anti-COX-1 and COX-2 eﬀects.
Flavocoxidshowednodetectableanti-COCOX-2activity
up to 50μg/mL demonstrated by a downturn in the curve
and accumulation of oxygen in the assay (Figure 3(a)). NS-
398, a strong selective COX-2 inhibitor, had a CO COX-2
IC50 of 0.095μg/mL. Compared with indomethacin, which
gave a CO COX-1 IC50 of 0.012μg/mL, ﬂavocoxid had an
IC50 of 25μg/mL. Therefore, indomethacin was more than
2000-fold stronger in inhibiting CO COX-1 than ﬂavocoxid.
These results suggest that ﬂavocoxid has little anti-CO
activityontheCOXenzymescomparedtowell-characterized
anti-inﬂammatory agents.
COX-1 and COX-2 Peroxidase Inhibitory Activity. It has been
shown that imbalances in COX-2 versus COX-1 inhibition
by selective COX-2 inhibitors in the generation of various
AA metabolites can contribute to edema, hypertension, and
myocardial infarctions [26]. Thus, the specially formulated,
proprietary mixture of baicalin and catechin has been
designed in an attempt to balance COX-1 and COX-2
metabolism of AA focusing on inhibition of the PO activity
oftheseenzymes. Acleavable,peroxidechromophore TMPD
was used to assess the anti-PO activity of ﬂavocoxid on
puriﬁed enzyme systems using COX-1 and COX-2.
Analysis of 90% pure baicalin used to formulate ﬂavo-
coxid was slightly more selective against the COX-2 (IC50 =
10 μg/mL) compared to COX-1 PO activity (IC50 = 13
μg/mL) activity (data not shown). The 90% pure catechin
used in the formulation, however, showed preferential
inhibitory activity towards the PO of COX-1 (IC50 = 2.5
μg/mL) versus COX-2 (IC50 = 15 μg/mL) (data not shown).
In an attempt to balance the PO COX-1 with that of PO
COX-2 inhibition activity, baicalin and catechin was com-
bined at a proprietary ratio to form ﬂavocoxid. Flavocoxid
showed relatively balanced inhibition of both COX-1 and
COX-2 PO activities with IC50s of 12.3 and 11.3μg/mL,
respectively (Figure 3(b)). These results as well as the relative
lack of CO activity on COX-1 and COX-2 suggest that
ﬂavocoxid exerts its eﬀects via modulation of the PO activity
of these enzymes.
5-LOX Inhibitory Activity. NSAIDs and COX-2 inhibitors do
not inhibit the 5-LOX pathway to prevent the accumulation
of leukoattractive and vasoconstrictive LTs [27]. Inhibition
of COX-1 and COX-2 by NSAIDs or selective COX-2
inhibitors has also been shown to “shunt” AA metabolism
down the 5-LOX pathway, resulting in an overabundance
of these fatty acid metabolites which can adversely aﬀect
multiple organs [28]. Increased levels of LTs are associated
with a variety of pathological conditions including asthma,
gastric ulcerations, renal insuﬃciency, and cardiovascular
complications [29, 30]. Cyclooxygenase enzyme inhibition
h a sa l s ob e e ns h o w nt oi n c r e a s et h el e v e lo fL T B 4 in synovial
ﬂuid, perhaps inducing further damage to cartilage [31].
Flavocoxid was titrated along with puriﬁed 5-LOX enzyme
i nt h ep r e s e n c eo fa no x y g e ns e n s i n gc h r o m o g e nin vitro to
detect the formation ofunstable HPETEs, an intermediate in
the formation of LTs.
Individual tests of baicalin and catechin revealed dif-
ferences in 5-LOX inhibitory capacity. Baicalin exhibited a
relatively strong inhibition of the 5-LOX enzyme with an
IC50 of 65 μg/mL in comparison to catechin (IC50 = 300
μg/mL) (Figure 3(c)). Flavocoxid, presumably reﬂecting the
ratio of these two molecules in the formulation, inhibitedMediators of Inﬂammation 5
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Figure 3: (a) Flavocoxid (0, 0.1, 1, 10, 50 μg/mL) COX-1 (
￿)a n dC O X - 2(  ) cyclooxygenase (CO) inhibition versus indomethacin (0,
3.6, 18, 36, 180, 360 ng/mL,
￿) and NS-398 (0, 3.1, 15.7, 31.4, 157, 314 ng/mL,
￿). (b) Flavocoxid (0.1, 0.5, 1, 2, 5, 10, 50, 100, 500 μg/mL)
COX-1 (
￿)a n dC O X - 2(
￿) peroxidase (PO) inhibition. (c) Inhibition of 5-Lipoxygenase for phenidone (•), baicalin (
￿), ﬂavocoxid (
￿),
catechin ( ), ibuprofen (+), and celecoxib (
￿) at 0.1, 0.2, 0.5, 1, 5, 10, 50, 100, 500μg/mL.
the 5-LOX enzyme with an IC50 of 110μg/mL. With the
exception of the known 5-LOX inhibitor, phenidone (IC50 =
1.3μg/mL), used as a positive control in these assays,
no other NSAID or selective COX-2 inhibitors, including
rofecoxib, valdecoxib, diclofenac, meloxicam, and aspirin
(datanotshown),showedanyanti-5-LOXactivity.Ibuprofen
with a small amount of 5-LOX inhibition at the highest
concentration tested (no IC50 could be determined) is
also shown in comparison to celecoxib (Figure 3(c)). These
results suggest that ﬂavocoxid also modulates the formation
ofLTsfrom5-LOXandmaypreventanaccumulationofthese
key inﬂammatory factors which contribute to tissue damage
through a putative 5-LOX shunt seen with NSAIDs.
Antioxidant Capacity. Nonenzymatic lipid peroxidation is
another important pathway of AA metabolism. When ele-
vated AA is present in organisms and it is exposed to ROS,
F2-isoprostanes and 4-hydroxynonenal (HNE) are produced
along with elevated malondialdehyde (MDA) in the presence
ofepinephrine and collagen[32].These oxidativeconversion
products are elevated in the synovial ﬂuid, synoviocytes,
and serum of OA patients when compared to healthy
control subjects and have been shown to stimulate the
production ofcartilage-degrading matrix metalloproteinases
[33]. No NSAIDs used in the treatment of OA possess
potent antioxidant properties which could potentially damp
inducible inﬂammation [27]. Flavocoxid modulates the
production of inﬂammatory cytokines and inducible nitrous
oxide synthase (iNOS) in cell assays presumably through an
antioxidant mechanism of action [5, 34], butthe extent of its
antioxidant capacity has never been investigated. To evaluate
the antioxidant capacity of ﬂavocoxid, a number of in vitro
antioxidant assays were used.
The ORACtotal for ﬂavocoxid was found to be higher
than the control antioxidants vitamin C (ORACtotal = 2000
μmolTE/g) and vitamin E (ORACtotal = 1100μmolTE/g) at
3719μmolTE/g with the ORAClipo (19μmolTE/g) contribut-
i n gl i t t l et ot h eo v e r a l lO R A Cs c o r e( Table 1). Flavocoxidhad6 Mediators of Inﬂammation
Table 1
ORAChydro
(μmolTE/g)
ORAClipo
(μmolTE/g)
ORACtotal
(μmolTE/g)
HORAC
(μmol
CAE/g)
NORAC
(μmol
TE/g)
SORAC
(kunit
SODeq/g)
FRAP
(μmol
TE/g)
TEAC
(μmol
TE/g)
DPPH
(μmol
TE/g)
ﬂavocoxid 3700 19 3719 1326 1936 27 1145 2456 767
ORAChydro: Oxygen Radical Absorbance Capacity reﬂects water-soluble antioxidant capacity; ORAClipo: Oxygen Radical Absorbance Capacity lipid-soluble
antioxidant capacity;ORACtotal:C o mbin edO R A C hydro and ORAClipo; HORAC:hydroxyl radicalabsorbance capacity;NORAC: peroxynitrite radicalaverting
capacity; SORAC: superoxide radical averting capacity; FRAP: ferric reducing/antioxidant power; TEAC: trolox equivalent antioxidant capacity; DPPH: 2,2-
di(4-tert-octylphenyl)-1-picrylhydroxyl assay;TE: trolox equivalents; CAE: caﬀeic acid equivalents; SODeq: superoxide dismutaseequivalents.
a HORAC value of 1326μm o lC A E / gf o rh y d r o x y lr a d i c a l s ,
which have also been implicated in joint damage. Similarly,
peroxynitrite may cause chondrocytes to decrease synthesis
of cartilage proteoglycan. Flavocoxid, with a NORAC value
of1936μmolTE/g,hasahighcapacitytoneutralizeperoxyni-
trite radicals. On the contrary, superoxide radical scavenging
capacity (SORAC) is relatively low for ﬂavocoxid (Table 1).
Shieh et al. [35] found that baicalein had a much higher
superoxide anion capacity compared to baicalin. This may
explain the relatively low SORAC value of ﬂavocoxid, as
baicalin, rather than baicalein, the gut bacterial breakdown
product absorbed systemically from ﬂavocoxid, was tested in
this assay. With respect to DPPH, our results are consistent
with others thatshow baicalinand epicatechin, thestereoiso-
mer of catechin, to be strong DPPH scavengers [36]. Flavo-
coxid also showed a high FRAP value. Our results also show
that ﬂavocoxid has a high TEAC of 2456μmolTE/g (Table 1).
Nitrite Suppression by Flavocoxid. Stable nitrite is used as
a measure of NO produced from iNOS from synovial
macrophages in OA [37]. Nitric oxide may be involved
in the destruction of proteoglycan in cartilage by induc-
ing the production of matrix metalloproteinase [38]. To
assess ﬂavocoxid’s eﬀect on the production of this highly
reactive oxidative molecule, LPS-stimulated rat peritoneal
macrophages expressing higher levels of iNOS were used in
thepresenceof increasing levelsofthe ﬂavonoidpreparation.
Nitrite measured by Griess reaction and subsequent spec-
trophotometric analysis measured ﬂavocoxid’s NO damping
capacity.
When ﬂavocoxid was titrated into cultures, it suppressed
nitrite production in a dose-dependent manner with an IC50
of 38μg/mL compared to cultures with LPS alone (P<
.05) (Figure 4), suggesting that ﬂavocoxid downregulates
the production of or neutralizes NO directly. Flavocoxid’s
activity in reducing NO production through damping of
iNOS [5] or through inactivation of NO by a direct
antioxidant eﬀect could help prevent to breakdown of the
proteoglycan in cartilage.
FlavocoxidEﬀectsonCox-1and Cox-2GeneExpression. Indu-
cible inﬂammatory genes are generally up-regulated by
the generation of ROS which induce nfκb expression and
activation by release of cytosolicIκBα-bound NFκBf r o mt h e
cytoplasm and subsequent translocation to the nucleus [27].
Cytokine (il-1β, il-6 and tnfα)a sw e l la scox-2, 5-lox and inos
genes have an NFκB binding site in their promoter regions.
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Figure 4: Nitrite levels in rat peritoneal macrophages exposed to
ﬂavocoxid(F) at10,20,50,100,200,and500μg/mL in the presence
of lipopolysaccharide (LPS).
Cyclooxygenase-1 gene expression is not inducible, but is
regulated through intron elements to yield constitutively
produced protein in many cell types. Flavocoxid is known to
damp inducible inﬂammatory gene and protein production
[5], but has not been compared directly to other NSAIDs or
analgesics for this activity. Therefore, ﬂavocoxid was added
to PBMCs at a ﬁxed concentration and compared directly
to celecoxib, ibuprofen, and acetaminophen for its eﬀects on
cox-1 and -2 expression.
W h e nﬂ a v o c o x i dw a sa d d e da t3μg/mL into cultures of
PBMCs stimulated with LPS, there was a 20-fold down-
regulation of cox-2 (Figure 5), but only a 3-fold reduction
in cox-1 expression. At the same concentration, celecoxib,
ibuprofen, and acetominphen did not reduce cox expression.
In fact, celecoxib and ibuprofen increased cox-2 expression
2 to 3 fold with acetaminophen exhibiting less than a
doubling of gene expression. Celecoxib, ibuprofen, and
acetaminophen also increased cox-1 expression 1.2-, 5-, and
8-fold, respectively (Figure 5). These results suggest that
ﬂavocoxid may modulate inﬂammatory metabolites, such as
PG, by reducing cox gene expression compared to celecoxib,
ibuprofen and acetaminophen which cause increased levels
of cox-1 and cox-2 expression.
4.Discussion
An overabundance of AA in the general population’s diet
of Western countries has shifted the balance of fatty acidMediators of Inﬂammation 7
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Figure 5: Eﬀect of ﬂavocoxid versus celecoxib, ibuprofen, and
acetominophen on cox-1 (gray) and cox-2 (black) gene expression.
metabolism toward an increase in proinﬂammatory metabo-
lite generation via the COX and 5-LOX enzymatic pathways
[39, 40]. This has been accompanied by an increased
generation of lipid peroxidation products by AA-oxidation
as a result of poor antioxidant status. There is a strong link
between metabolic defects in fatty acid metabolism or an
overabundance of dietary fatty acids and the incidence of
OA. For example, fatty acid levels in bone have been shown
to be 50–90% higher in OA patients compared to controls
[41]. Poor oxidative status, as well as the production of
oxidized lipids from AA, has also been linked to chondrocyte
apoptosis, activation of latent matrix metalloproteinases,
and cartilage matrix degradation due to upregulation of
inﬂammatory gene expression [38, 42]. Therefore, an anti-
inﬂammatory agent with pleiotropic activities could help
modulate these predisposing dietary factors. Kim et al.
[43] reviewed this subject and found that a wide variety
of ﬂavonoids modulate the activities of AA metabolizing
enzymes, such as PLA2, COX, and 5-LOX and the NO
producing enzyme, iNOS. We sought to test ﬂavocoxid,
a prescription product, to determine its impact on these
pathways which contribute to OA.
Lipid peroxidation, as a result of poor oxidative status,
destabilizes cell membranes leading to induction of calcium-
dependent PLA2 which hydrolytically attacks phospholipids
leading to the generation of AA [44]. In joints, breakdownof
chondrocyte cell membranes providesthe substrate for PLA2
conversion to AA [45]. With their potent antioxidant capac-
ity, ﬂavonoids can interrupt the oxidative generation of AA
from phospholipids and reduce the downstream production
of inﬂammatory metabolites from AA metabolism, oxidative
damage, and induction of inducible inﬂammatory pathways
[34, 46–49]. In our study, ﬂavocoxid reduced both PLA2
activity and nitrite levels in macrophages. This suggests that
ﬂavocoxid may act to limit the conversion of phospholipids
from damaged cell membranes to AA upstream of the COX
and 5-LOXmetabolicpathways.Inaddition,thereductionin
nitrite, thestablebreakdownproductofNO,maypreventthe
production of matrix metalloproteinase from macrophages
present in the synovium [37]. In support of these ﬁndings,
ﬂavocoxid was previously shown to reduce iNOS protein
production by an antioxidant mechanism [5]. Since it is also
known that NO levels are positively aﬀected by increases
in cytokine production [50], ﬂavocoxid’s cytokine-reducing
eﬀect [5, 48] may inhibit the increase in inos expression and
NO levels.
The current experiments demonstrate that, unlike
NSAIDs, ﬂavocoxid does not appreciably inhibit CO
metabolismofAAtoPGG2.Ratheritactsviaabalancedanti-
PO inhibitory on the COX enzymes. There are conﬂicting
reports that the PO and CO activities are separable in the
COX enzymes [51, 52]. Individual PO and CO mutants have
been created in vitro [53]. When the PO site was mutated,
there were delays in the metabolite generation implying
that some other cellular peroxidase may compensate for
the mutated activity. Therefore, CO and PO activities are
coupled in the COX-1 and COX-2 enzymes to eﬃciently
produce end products [54]. The inhibition of one or both
activities reﬂects modulation of overall COX enzyme activity
[55]. Flavocoxid was shown to downregulate both PGE2 and
LTB4 productionin celland animals modelsofinﬂammation
[5, 34, 48, 56]. Flavocoxid did not, however, block the
production of TxA2 in a human platelet function study [57],
suggesting the presence of another compensatory mecha-
nism that bypasses its PO inhibitory activity on the COX
enzymes to allow for generation of the PGH2 intermediate
whichisthenconvertedtoTxA2.Thisdiﬀerentialmechanism
of PO versus CO inhibition also explains ﬂavocoxid’s lack of
interactionwithaspirin sinceaspirinspeciﬁcallymodiﬁes the
COX-1 binding site [57].
It has been demonstrated that patients with OA of the
knee have higher than normal levels of oxidative species
and antioxidant enzymes in their synovial ﬂuid [58]. Pure
tea catechins and (+)-catechin, found in ﬂavocoxid, are
known to be strong antioxidants with high ORAC scores
between 13,000 and 20,000μmolTE/g, respectively [59, 60].
These catechin molecules also have high FRAP and DPPH
values. Baicalin was shown, however, to have a much lower
ORAC score of ∼365μmolTE/g [61]. Although ﬂavocoxid
has a lower antioxidant capacity compared to catechin itself,
the ORACtotal score is still approximately 3 times that of
mixed tocopherols and almost twice that of vitamin C.
Altavilla et al. [5] showed that ﬂavocoxid’s antioxidant
capacity reduced cellular conversion of AA to MDA in
the presence of epinephrine and collagen normally elevated
in OA patients. Nuclear factor-κBb i n d i n gt oam o d e l
substrate and IκBα protein expression was also elevated in
the same experiments suggesting that ﬂavocoxid restored
the cytoplasmic inhibitory control of this ROS-inducible
transcription factor. An impure mixture of baicalin and
catechin has also been shown to decrease oxidative species
in synovial ﬂuid in humans with OA suggesting a direct
antioxidant eﬀect on the level of ROS species in the joint8 Mediators of Inﬂammation
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[62]. Flavocoxid’s strong antioxidant capacity also aﬀects
inducible inﬂammatory gene and protein expression.
Previous experiments have demonstrated that ﬂavocoxid
downregulates COX-2 and 5-LOX protein expression, but
not COX-1 [5]. Tseng-Crank et al. [63] recently showed
that a combination of baicalin and catechin dramatically
decreases cox-2 and cytokine expression, but has only a
marginal eﬀect on cox-1 in a human cell model. We
found that ﬂavocoxid also decreases cox-2 expression by
∼20-fold in human PBMCs, while having a much smaller
eﬀect on cox-1 (∼3-fold). This work showed, however, that
celecoxib and ibuprofen promoted noticeable increases in
cox-1 and cox-2, suggesting both therapies could potentially
contribute to inducible pathways of inﬂammation. When
combined with a strong antioxidant capacity and previous
ﬁndings on damping inﬂammatory gene expression [5, 34,
48, 63], the results presented here suggest that ﬂavocoxid
acts through an antioxidant mechanism to control inducible
inﬂammatory gene expression in addition to modulating
fatty acid processing enzymes including 5-LOX.
Wallace and Ma [64] suggested that metabolic shunting
towardthe5-LOXpathwaywasamajorcontributortogastric
injury in humans. When gastric mucosa was stimulated with
calcium ionophore or arthritis patients were exposed to
NSAIDs, there was a reduction in the release of PGE2 and an
increase in leukoattractive LTB4 and vasoconstrictive LTC4
and LTD4 [65, 66]. Compatible with these ﬁndings, a long-
term clinical trial has shown that ﬂavocoxid has signiﬁcantly
fewer upper gastrointestinal adverse events compared to
naproxen [12, 67]. Similarly, a phase-IV-like postmarketing
studyshowed thatﬂavocoxidwaswell-toleratedinpreviously
NSAID (including celecoxib) intolerant patients who ceased
or decreased gastroprotective use by over 30% [11]. Walton
et al. [68] performed a cost analysis which suggests that
this safety advantage would make ﬂavocoxid less expensive
comparedtogenericnaproxenin amedicare populationover
a one-year time frame. A well-controlled endoscopy study
is needed to deﬁnitively judge ﬂavocoxid’s gastrointestinal
safety.
Gambaro [69] has suggested that dual inhibition of COX
and 5-LOX enzymes may also oﬀer advantages in terms
of renal toxicity, which may also aﬀect CV complications.
Both NSAIDs and selective COX-2 inhibitors are known to
cause renal damage. Levy et al. [12, 67] found that there
were statistically fewer incidences of edema for ﬂavocoxid
compared to naproxen. Though not reaching statistical
signiﬁcance, creatinine levels trended lower in the ﬂavocoxid
group and higher in the naproxen group. Speciﬁc well-
controlled studies in renal compromised subjects are needed
to truly assess ﬂavocoxid’s safety in these patients.
Flavocoxid is the only currently marketed prescription
anti-inﬂammatory agent that modulates COX enzymes via
an anti-PO activity, inhibits 5-LOX-mediated LT produc-
tion, and has a broad, strong antioxidant activity which
downregulates inducible inﬂammatory gene expression as
well as neutralizes ROS thereby preventing the conversion
of AA to oxidized lipids. Flavocoxid’s putative mechanism
of action is shown in Figure 6 and is presumed to be theMediators of Inﬂammation 9
reason for the favorable safety proﬁle seen in clinical trials
and postmarketing surveillance. Work is currently underway
to determine if this broad-based mechanism of action can
preserve cartilage structure.
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